Bexotegrast, is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis (IPF). Bexotegrast has been administered to over 600 study participants to date, including healthy volunteers and patients, with no drug-related severe or serious adverse events reported to date.
Berkshire’s Decline, Buffett’s Asian Surge: An Intriguing Narrative Of Calculated Investment Strategies
Undeterred by market fluctuations, Buffett remains focused on the Japanese market, aligning with Berkshire Hathaway's value-oriented strategy and desire for diversification.
Macroeconomic factors such as a weaker yen and a robust tourism industry have bolstered the performance of Japanese stocks.
